Blockchain Registration Transaction Record

Soligenix CEO: Patient-Centric Reformulation Is Key to Drug Success

Soligenix CEO advocates patient-centric drug reformulation to improve treatment access and adherence for rare diseases. Learn how subcutaneous delivery transforms chronic care.

This news matters because it addresses a fundamental flaw in traditional drug development: creating effective treatments that fail in real-world use due to impractical delivery methods. For patients with chronic rare diseases like Behçet's Disease or cutaneous T-cell lymphoma, the burden of frequent clinic visits for IV treatments can be overwhelming, leading to poor adherence and diminished quality of life. Soligenix's shift toward home-administered subcutaneous injections represents more than convenience—it could determine whether life-saving therapies actually reach and benefit those who need them. This patient-centric approach has broader implications for healthcare costs and outcomes, as treatments designed for real-world use reduce hospital visits and improve long-term management. In an era where drug prices and accessibility are under scrutiny, innovations that prioritize patient experience while maintaining efficacy could become the new standard for successful therapies.